Control of PKA signaling by the Ubiquitin proteasome system (UPS) by Rinaldi, Laura
1 
 
UNIVERSITY OF NAPLES “FEDERICO II” 
 
PhD Program 
Molecular Pathology and Physiopathology 
  
School of Molecular Medicine 
XXVIII Cycle 
Control of PKA signaling by the Ubiquitin 
proteasome system (UPS) 
 
Supervisor                                                 Candidate 
Prof. Antonio Feliciello                    Dr. Laura Rinaldi 
PhD coordinator 
Prof. Vittorio Enrico Avvedimento 
 
Academic year 2014-2015 
2 
 
TABLE OF CONTENTS 
CONTENTS……………………………………………………………p.2 
ORIGINAL PUBBLICATIONS……………………………………….p.4 
LIST OF ABBREVIATIONS………………………………………….p.5 
ABSTRACT……………………………………………………………p.6 
 
1)INTRODUCTION…………………………………………………..p.7 
1.1 The cAMP-dependent signal transduction pathway………….p.8 
1.2 Protein Kinase A (PKA)………………………………………….p.11 
1.3 The ubiquitin proteasome system (UPS)………………………p.15 
1.4 Carboxy-terminus of HSP70 interacting protein (CHIP)…......p.18 
 
2)AIM OF THE STUDY………………………………………………p.20 
 
3)RESULTS……………………………………………………………p.22 
3.1 The UPS is responsible for PKA-C degradation……………….p.23 
3.2 PKA-C is ubiquitinated in response to cAMP stimulus………..p.25 
3.3 PKA-C interacts with the E3 ligase CHIP and the molecular 
chaperone HSP70…………………………………………………….p.27 
3.4 CHIP ubiquitinates PKA-C……………………………………….p.30 
3.5 CHIP degrades PKA-C…………………………………………...p.32 
3.6 Inhibition of HSP70 inhibited PKA-C degradation by cAMP….p.34 
3.7 HSP70/CHIP complex regulates cAMP-dependent CREB 
phosphorylation………………………………………………………..p.35 
3 
 
3.8 HSP70/CHIP complex regulates c-fos transcription……………p.38 
3.9 HSP70 specific inhibitor prevent PKA-C degradation and promotes 
CREB phosphorylation in mouse brain……………………………….p.40 
3.10 HSP70 inhibitor enhances L-LTP in mouse brain……………..p.43 
 
4) CONCLUSIONS AND DISCUSSION……………………………..p.44 
 
5) METHODS…………………………………………………………...p.49 
 
6) REFERENCES………………………………………………………p.54 
 
 
 
 
 
 
 
 
 
 
 
4 
 
ORIGINAL PUBBLICATIONS 
1. Lignitto L, Arcella A, Sepe M, Rinaldi L, Delle Donne R, Gallo A, 
Stefan E, Bachmann VA, Oliva MA, Tiziana Storlazzi C, L'Abbate 
A, Brunetti A, Gargiulo S, Gramanzini M, Insabato L, Garbi C, 
Gottesman ME, Feliciello A. (2013) Proteolysis of MOB1 by the 
ubiquitin ligase praja2 attenuates Hippo signalling and supports 
glioblastoma growth. Nature Communication.2013, 4:1822. 
Doi:10.1038/ncomms2791. 
 
2. Sepe M, Lignitto L, Porpora M, Delle Donne R, Rinaldi L, 
Belgianni G, Colucci G, Cuomo O, Viggiano D, Scorziello A, 
Garbi C, Annunziato L, Feliciello A.(2014) Proteolytic control of 
neurite outgrowth inhibitor NOGO-A by the cAMP/PKA pathway. 
Proc. Natl. Acad. Sci. 2014, 111(44):15729-15734. 
 
3. Rinaldi L, Sepe M, Donne RD, Feliciello A.(2015) A dynamic 
interface between ubiquitylation and cAMP signaling. Front. 
Pharmacol. 2015, 6:177. 
 
4. Rinaldi L.*, Delle Donne R.*, Sepe M., Porpora M., Garbi C., 
Chiuso F., Gallo A., Parisi S.,  Russo L., Bachmann V., Huber R. 
G., Stefan E., Russo T. and  Feliciello A.(2016) praja2  regulates  
KSR1 stability and mitogenic signaling . Submitted to Cell Death 
and Desease. 
 
5. Rinaldi L., Delle Donne R., Sepe M., Porpora M., Sauchella S., 
Chiuso F., Nisticò R., Piccinin S., Stefan E., Feliciello A. Control 
of PKA signaling by the Ubiquitin proteasome system (2016). 
Manuscript in preparation. 
 
 
 
 
 
 
5 
 
LIST OF ABBREVIATION 
PDE Phosphodiesterase 
AC Adenylyl cyclase 
GPCR G protein coupled receptor  
PKA Protein kinase A 
UPS Ubiquitin Proteasome System 
CHIP C-terminus of Hsc70 Interacting protein 
cAMP cyclic AMP 
PKA-C Catalytic subunit of protein kinase A 
FSK Forskolin 
HSPI Hsp70 Inhibitor 
  
6 
 
ABSTRACT 
Stimulation of G protein coupled receptors(GPCRs) causes the 
increase of cAMP intracellular levels. The main effector of cAMP 
signaling is Protein kinase A (PKA), which, in its inactive form, is 
constituted by two catalytic (Cs) and two regulatory (Rs) subunits. The 
binding of cAMP to the Rs causes the disassembly of the holoenzyme 
and the release of the Cs in the cytoplasm, with the conseguent 
phosphorylation of a wide array of cellular substrates. The duration and 
the amplitude of the PKA signaling is dependent on the amount of free 
C subunits in the cell. Here I contributed to identify a novel mechanism 
of PKA signaling attenuation, based on the ubiquitination and 
degradation of the C subunit of PKA (PKA-C). Stimulation of GPCRs 
induced  poly-ubiquitination and degradation of PKA-C , causing the 
decrease of PKA substrates activation. I identified the complex 
HSP70/CHIP as responsible for this ubiquitination. Interfering with CHIP 
expression or inhibiting the HSP70 activity impeded PKA-C 
ubiquitination and sustained PKA signaling. 
Thus the HSP70/CHIP complex regulates the total concentration of C 
subunits, tuning the strength and duration of PKA signaling in response 
to cAMP. 
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1.INTRODUCTION 
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1.1 The cAMP-dependent signal transduction pathway 
Extracellular signals, such as hormones and growth factors, regulate 
multiple cellular activities. Intracellular transduction systems receive the 
signals and transmit them to elicit specific biological responses. Since 
living cells are exposed to a wide variety of simultaneous stimuli, the 
tight regulation of the intracellular transduction pathways is crucial for 
the appropriate response. 
Cell surface signal transducing systems are the most common way for 
information to flow into the cell. In these systems, plasma membrane 
receptors recognize extracellular signals and, in turn, activate 
intracellular messengers, also known as second messengers.  
The first second messenger to be identified was cyclic adenosine 3′,5′-
monophosphate (cAMP)  (1). Since its discovery, all the elements of the 
cAMP transduction pathway have been intensively studied, generating 
a complex and finely regulated network of scaffolding and regulatory 
proteins (2) . The intracellular levels of cAMP are controlled by the 
balance between two classes of proteins: the Adenylyl Cyclases (ACs), 
enzymes that convert ATP in cAMP, and the Phosphodiesterases 
(PDEs), enzymes that hydrolyze the 3’-5’ phosphodiester bond in 
cAMP, producing 5’ AMP  (3). 
G protein coupled receptors (GPCRs) belong  to a large family of 
proteins characterized by seven trans-membrane helices (7 TMs). 
GPCRs transduce signals from the extracellular microenvironment to 
inside cell  (4). GPCRs include receptors for sensory signal mediators, 
for biogenic amines (dopamine, epinephrine, isoproterenol), and for 
peptide hormones ( FSH, GH).  
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The binding of extracellular ligands to GPCR at cell membrane causes 
a conformational change in the receptor, allowing the binding to the α 
subunit of the G proteins (Gαs). The activated Gα exchange the GDP 
with GTP triggering the dissociation of the α subunit from the Gβ and 
Gγ subunits. The dissociated Gα  activates the Adenylate Cyclase (AC), 
which generates cAMP at discrete points of the plasma membrane  (5) . 
cAMP acts through three distinct classes of effectors: cAMP-dependent 
protein kinase (PKA), RAP exchange proteins (EPACs), and cAMP 
gated ion channels (cNGC)  (6). 
Following the stimulation of GPCRs, PKA translocates into the nucleus. 
Once in the nucleus it stimulates the transcription of several factors, 
through phosphorylation of the cyclic AMP-responsive element binding 
protein (CREB) at Ser 133   (7) . Phosphorylated CREB binds to cAMP 
response elements (CREs) of gene promoters and recruits histone 
acetyl transferases CREB binding protein (CBP) and p300 to activate 
the transcription of target genes  (8). 
Continuous or repeated pulses of hormone stimulation down-regulate 
GPCR activation. This phenomenon is called receptor desensitization  
(9). Desensitization can be homologous or heterologous, the first one 
consists in a loss of response to agonists that act to a particular subtype 
of GPCRs, whereas the heterologous desensitization refers to a more 
general effect involving the simultaneous loss of agonists 
responsiveness at multiple GPCRs (10). The deregulation of 
cAMP/PKA signaling, or genetic mutation of its components are 
associated with pathological conditions, such as cardiac dysfunctions  
(11), familial breast cancer  (12)  and schizophrenia (13). 
 
10 
 
 
                                         Rinaldi et al. Frontiers in Pharmacology 2015 
 
Figure 1. cAMP signaling The binding of a ligand to the GPCR causes the 
dissociation of heterotrimeric G proteins and the cosequent activation of AC by Gα 
subunit. AC converts ATP into cAMP; cAMP binds the regulatory subunits of PKA, 
eliciting the dissociation from the catalytic subunits. The free catalytic subunits 
phosphorylate a wide array of substrates, evoking plenty of biological responses. 
cAMP levels are regulated by PDEs that converts the cAMP in 5’ AMP.  
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1.2  Protein Kinase A (PKA) 
In eukaryotes most of the effects elicited by cAMP depend on the 
activation of PKA. PKA is an holoenzyme constituted by two regulatory 
(Rs) and two catalytic (Cs) subunits. Rs exist in two major forms: RI and 
RII, each form have two different subtypes, alpha and beta, and every 
isotype is encoded by a different gene. Depending on type of R 
subunits (RI or RII) present in the holoenzyme, PKA is classified as type 
1 and type 2, with different sensitivity to cAMP activation and different 
localization  (14).  
Catalytic subunits exist in three different subtypes, alpha, beta and 
gamma. C  and C  subunits are highly homologous (93%), exibit 
similar substrate specificity and  are broadly expressed in all tissues 
(Ulher M.D., et al. 1986) (15). The C  subunit is more tissue-specific 
and less sensitive to PKA specific inhibitors, compared to C  and C   
(16). 
The activity of PKA is modulated by a family of proteins called PKA 
inhibitors (PKI). These proteins are characterized by a heptapeptide 
sequence (LLRASLG) called Kemptide motif. This motif acts as pseudo-
substrate, it binds to and inhibits the C subunit  (17). 
The binding of two molecules of cAMP to each R subunit causes the 
dissociation of the holoenzyme and release of the two active C 
subunits. Free C subunits catalyze the transfer of the terminal 
phosphate of ATP to a Serine/Threonine residue located at position 4 of 
the PKA consensus site (Arg-Arg-X-Ser/Thr) of the target protein. By 
phosphorylating intracellular substrates, PKA regulates essential 
aspects of cell physiology  (18).  
PKA C subunit  was the first kinase whose structure has been resolved 
by crystallography. This kinase  is composed by two lobes, the upper 
12 
 
lobe (residues 25-120) and the lower lobe ( 128-310), and the catalytic 
site is positioned between the two lobes. The key residues for kinase 
activity are the Asparagine-166, which serves as catalytic base, the 
Lysine-168 that neutralizes the negative charge of the ATP phosphate 
group during its transfer to the substrate and the Arginine-184 that 
chelates the Mg2+ ions  (19), (20). 
 
 
 
Figure 2. Schematic structure of PKA subunits Regulatory subunit of PKA 
is characterized by a dimerization domain at the N-terminal end of the protein, 
an auto-inhibitory domain and the two cAMP binding domains. 
The catalytic subunit has an ATP binding domain located at its the N-terminus, 
a substrate binding domain in the middle region and one R-binding domain at 
its C-terminus. 
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The functional and the  biochemical features of the PKA holoenzymes 
are mostly determined by the relative abundance of the intracellular Rs. 
The localization of PKA within the cell is mediated by scaffold proteins, 
called A-Kinase Anchor Proteins (AKAPs). AKAPs  belong to a group of 
proteins that share the common feature to target PKA in proximity of its 
substrates (21). Each AKAP contains a PKA-binding motif that binds the 
R subunit of PKA and a targeting domain that directs the kinase to 
specific subcellular compartments  (22). Moreover, AKAPs can organize 
multiplex signalling complexes at the precise site where the stimulus is 
generated, through the binding with other components of the cAMP 
cascade, as GPCRs, phosphodiesterase (PDEs), ACs, protein 
phosphatases  (14),(23). 
 
 
 
     A. Calejo and K. Taskén Front. Pharmacol, 2015 
Figura 3. AKAP transduceosome AKAPs role is to  target  PKA and its interactors 
to specific subcellular localizations. They can also function as signaling scaffolds for 
other signaling enzymes, this particular phenomenon compartimentalizes the signal 
making it faster and more efficient.   
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Following cAMP stimulation, PKA holoenzyme undergoes to 
phosphorylation at Ser 95 of RII subunits. As a consequence of this auto-
phosphorylation, the affinity between the catalityc subunits and the 
regulatory subunits decreases (24). The other two phosphorylation 
events occur at two sites of the catalytic subunit: Ser338 and Thr197. 
Phosphorylation of Ser338 is an essential step for correct folding of the 
kinase and for its activity  (25). 
Activation of PKA is followed by a refractory phase caused by different 
mechanisms: 1. activation of Ser/Thr phosphatases  (26); 2. activation of 
PDEs (27) ; 3. Downregulation of GPCRs  (28); 5. inhibition of ACs  (29) 
4. transcriptional regulation of components of the cAMP network  (30)  ; 
5. ratio between R and C subunits   (31). 
Dis-regulation of PKA is associated with a variety of pathological 
conditions. Thus, germline inactivating mutations or large deletions of the 
gene encoding for the RI  subunit (PRKAR1A) cause the Carney 
complex syndrome, a rare autosomal dominant syndrome, characterized 
by multiple endocrine tumors  (32). PRKAR1A inactivation and PKA 
dysregulation have been implicated also in various types of 
adrenocortical pathologies associated with ACTH-independent Cushing 
syndrome (AICS). More recently, somatic mutations of PKA C  subunit 
have been associated with the pathogenesis of cortisol-producing 
adrenocortical tumors. These mutations abolish the interaction between 
the R and C subunits, causing a long-lasting cAMP-independent 
activation of the PKA (33) . 
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1.3 The ubiquitin proteasome system (UPS) 
The ubiquitin-proteasome system is an important mechanism of protein 
degradation that is involved in the homeostasis of numerous cell 
functions, such as cell growth, differentiation, survival and metabolism.  
Proteolysis via UPS involves the modification of the substrate proteins 
by the covalent attachment of multiple ubiquitin molecules (poly-
ubiquitination). The ubiquitin tagged protein is eventually targeted to 
proteasomal degradation  (34). 
The ubiquitynation is a process mediated by the attachment of ubiquitin 
to the amino group of lysine residues of a target protein. This process 
requires a series of ATP dependent enzymatic steps catalyzed by E1 
(ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme) and E3 
(ubiquitin ligating enzyme). The E3 ubiquitin ligase enzyme, which tags 
the substrate with the ubiquitin molecules, determines the target 
specificity of the process  (35). 
E3 ligases belong to four different families: HECT (Homologous to the 
E6-AP Carboxyl Terminus), RING (Really Interesting New Gene), U-
box, and PHD (plant homeodomain). The HECT is the only E3 ubiquitin 
ligases that directly ubiquitinate the substrates. They function similarly 
to E1 and E2 enzymes, as they contain a central cystein residue that 
acts as an acceptor for ubiquitin.  
The RING E3 ligases constitute the largest family characterized by a 
cystein-rich zinc binding domain. They do not have a direct role in 
protein ubiquitination, instead they act as scaffold, helping the substrate 
proteins and the E2 enzymes to interact  (36).  
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The U-box is a 74 amminoacid domain, structurally related to the RING 
finger domain. Like RING finger E3s, they facilitate the E2 interaction 
with the substrate  (37). 
All the modifications described can involve the attachment of both  a 
single ubiquitin molecule (mono-ubiquitination) and a multiple ubiquitin 
moieties (poly-ubiquitination) (38). E3 ubiquitin ligases can catalyze 
either mono- and poly-ubiquitination.  
The destiny of a polyubiquitinated protein depends of which lysine 
residue of the ubiquitin molecules is attached to the substrate. Ubiquitin 
molecules linked through the lysine at position 48 (K48) target proteins 
to the proteasome. However, all the lysines of the ubiquitin molecule 
can be involved in the covalent binding to the next ubiquitin molecule 
(K6, K11, K27, K29, K48, and K63-)  (39) 
Poly-ubiquitination of a protein is mostly related to protein degradation 
through the proteasome. Alternatively, polyubiquitinated proteins can 
also follow a non-degradative pathway  (40). In particular, this 
mechanism can control the intracellular trafficking of the target protein 
or its activity  (41). In this case, de-ubiquitinating enzymes (DUBs) can 
remove the ubiquitin chain and restore the localization/activity of the 
modified proteins  (40). 
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Domagoj Vucic, Vishva M. Dixit & Ingrid E. Wertz “Nature Reviews Molecular Cell 
Biology 2011” 
Figure 4. Schematic representation of Ubiquitin system The conjugation of 
ubiquitin molecules to substrates requires coordinated action of three 
enzymes: the ubiquitin activating enzyme (E1), the ubiquitin conjugating 
enzyme E2 and the E3 ubiquitin ligase, that links the ubiquitin molecules to 
substrates. Once ubiquitinated, the proteins can be degraded by the 
proteasome or de-ubiquitinated by specific DUB enzymes. 
 
 
 
 
 
 
 
 
 
18 
 
1.4  Carboxy-terminus of HSP70 interacting protein (CHIP) 
CHIP (C-terminus of Hsc70 Interacting protein), also known as STIP1 
homology and U-Box containing protein 1 (STUB1), is a very conserved 
protein, ubiquitously expressed, that belongs to the family of U-box E3 
ubiquitin ligase. It binds to the molecular chaperone Hsc70, controlling 
both the ubiquitination and the turnover of the Hsc-70 bound clients 
(42). 
Heat shock cognate 70 (Hsc70) is a costitutively expressed member of 
the molecular chaperones Hsp70 family. It is an important member of 
the protein quality control system, and works together with a list of co-
chaperones to help the refolding of proteins, and to degrade the 
misfolded proteins  (43, 44). 
The concerted activity of Hsc70 and CHIP is fundamental to reduce, 
through the ubiquitin-proteasome system, the levels of disease-
associated and misfolded proteins, like the microtubule-binding protein 
tau, or the cystic fibrosis transmembrane conductance regulator  (45, 
46). CHIP also modifies Hsc70 by adding canonical and non canonical 
poly-ubiquitin chains (47), increasing Hsc70 activity and enhancing its 
turn-over  (48, 49).  
CHIP interacts with Hsc70 through a C-terminus located motif , 
composed of  8 residues (GPTIEEVD)  (50). A similar motif is present 
also in the Hsp90 molecular chaperone, allowing CHIP to ubiquitinate 
Hsc70- and Hsp90-bound substrates (51). The function of CHIP strictly 
depends on its capability to bind to Hsc70 or Hsp90. A tetratricopeptide 
repeat (TPR) domain located at the N-terminus of CHIP mediates the 
binding to HSP70/90. The TPR consist of 3 to 16 degenerate 34 
amminoacid motifs constituted by anti-parallel α-helical hairpins (52).  
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A U-box domain present at the C-terminus of CHIP displays   ubiquitin 
ligase activity. CHIP provides a direct link between the protein quality 
control system directed by chaperones and the proteasome system, 
and it is deputed to regulate the cellular balance between folding and 
degradation, playing a key role in the maintenance of cellular 
homeostasis.  
 Inactivating mutations in STUB1 gene have been recently linked with 
different form of ataxia and hypogonadism. In particular mutations in 
this gene cause spinocerebellar ataxia, autosomal recessive 16 
(SCAR16).  Loss of CHIP function in mice results in behavioral and 
reproductive impairment, miming the human ataxic phenotipe  (53, 54). 
 
 
             
Figure 5. Chaperone-directed E3-ubiquitin ligase CHIP (A) Model of CHIP 
E3–E2 complex. The model is a composite of crystal structures of the full-
length CHIP dimer bound to the C-terminal peptide of Hsp90 (magenta), and 
the crystal structure of a complex of the CHIP U-box dimer bound to the 
heterodimeric Lys63-specific E2 ubiquitin-conjugating enzyme Ubc13–Uev1a. 
The unusual asymmetric structure of CHIP allows it to bind to both C-terminus 
of an Hsp90 dimer, but to recruit only one E2 system. (B) Schematic figure 
showing how a client protein bound to Hsp90 could be polyubiquitinated by 
CHIP as a necessary prelude to degradation by the proteasome. U, ubiquitin 
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2.1 AIM OF THE THESIS 
The laboratory where I completed my PhD program is interested in the 
mechanisms underlying cAMP signaling in mammalian cells. In the last 
years, our attention was focused on the regulation of cAMP signaling by 
the UPS. In this context, it is emerging a reciprocal regulation between 
cAMP-PKA and the UPS at different levels, giving rise to a complex 
regulatory network that controls key biological activities. We have 
demonstrated that PKA stability and activity can be regulated by the 
UPS. Thus, the RING-H2 ligase praja2 once activated by PKA, primes 
R subunits to the UPS. By lowering the levels of inhibitory R subunits, 
praja2 increases PKA-dependent phosphorylation and downstream 
signaling(55) . 
The aim of my PhD project was to find a connection between the UPS 
activity and the stability of PKA catalytic subunit (PKA-C), identifying the 
E3 ubiquitin ligase responsible for PKA-C degradation and evaluating 
the physiological consequences of PKA-C regulation by the UPS.  
More specifically, my attention was focused on the following points: 
- Understand if PKA-C is a target of the UPS 
- Identify the E3 ubiquitin ligase that controls PKA-C stability 
- Analyze the complex formed by PKA-C and the E3 ligase. 
- Define the functional relevance of the PKA-C modulation by the 
UPS. 
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3.RESULTS 
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3.1 The UPS is responsible for PKA-C degradation. 
Given this role of cAMP and the proteasome in the regulation of the 
PKA regulatory subunits stability, I asked if PKA-C is also degraded by 
the UPS.  
To this aim, I treated HEK293 cells with Forskolin (FSK), a diterpene 
that activates the transmembrane adenylate cyclase, and analyzed the 
levels of PKA-C subunit in cell lysates. The data shown in Fig 6a and 
6b revealed that prolonged FSK treatments (for 6 and 9 hours) caused 
a severe decrease of PKA-C levels. To understand was involved in 
PKA-C degradation, the experiment was replicated by pre-treating the 
cells with MG132, a proteasome inhibitor. As shown in Fig 6a and 6b, 
the treatment with MG132 was sufficient to abrogate the PKA-C 
degradation induced by FSK. 
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a) 
                   
b) 
              
 
 
Fig.6. MG132 reverses cAMP dependent PKA-C degradation. a) 
HEK293 were treated with Forskolin (FSK, 40 uM) for the indicated 
times and harvested. Total lysates (20 ug) were immunoblotted with 
anti-PKA-C polyclonal antibody. Where indicated the cell were 
pretreated with MG131. b) Quantitative analysis of the experiment. 
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3.2 PKA-C is ubiquitinated in response to cAMP stimulus. 
Given the role of the proteasome in PKA-C degradation, the next 
step was to understand if PKA-C was ubiquitinated in response to 
cAMP stimulation. To test this hypothesis,  I performed in vivo 
ubiquitination assays. HEK293 cells were transfected with hemaglutinin 
(HA)-tagged ubiquitin, treated with FSK and harvested after 5’ to 60’ 
minutes of treatment. The lysates were immunoprecipitated with anti-
PKA-C antibody, and the precipitates were immunoblotted with anti-HA 
antibody.  Fig. 7 shows that FSK induces the accumulation of poly-
ubiquitinated form of PKA-C. 
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Fig 7. HEK293 were transfected with HA-ubiquitin. 24 hours after 
transfection cells, cells were treated with FSK (40uM) and harvested at 
the indicated time points. Lysates (1 mg) were immunoprecipited with 
anti-PKA-C antibody. The precipitates were immunoblotted with anti-HA 
and anti-PKA-C antibodies. 
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 3.3 PKA-C interacts with the E3 ligase CHIP and the molecular 
chaperone HSP70. 
Since PKA-C is efficiently ubiquitinated under cAMP stimulus, it was 
necessary to identify the E3 ligase responsible for this ubiquitination. By 
mass spectrometry analysis, I isolated several interactors of PKA-C. 
Among these, I found the E3 ligase CHIP and its molecular chaperone 
HSP70 as potential PKA-C interactors. These two proteins are known to 
form a dimeric complex, where HSP70 recognizes the target protein 
and the co-assembled CHIP ubiquitinates it. Therefore, I tested if 
HSP70, CHIP and PKA-C constitute a trimeric complex in cells.  First, I 
performed a co-immunoprecipitation assay using lysates from cells 
transfected with the CHIP and HSP70 target. Where indicated, cells 
where stimulated with FSK. As shown in fig. 8, PKA-C is bound to 
HSP70, both under basal conditions or following FSK stimulation. CHIP 
was present in the HSP70 immunoprecipitates. In contrast, a CHIP 
mutant lacking the HSP70 binding activity (CHIP-K30A) was not 
recruited within the HSP70/PKA-C complex, indicating that HSP70 was 
necessary for CHIP binding to PKA-C. 
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Figure 8. HEK293 cell were transfected with V5-HSP70 and Myc-CHIP 
(wt or mutant K30A). 24 hours after transfection, cells were treated with 
FSK for 15 minutes and harvested. Lysates were immunoprecipited with 
anti-V5 antibody and the precipitates were immunoblotted with the 
described antibodies. 
 
To understand if the recruitment of CHIP on the PKAc/HSP70 complex 
was regulated, I performed co-immunoprecipitation assays using 
antibodies against PKA-C. As shown by figure 9, FSK treatment 
increases the levels of CHIP bound to PKA-C/HSP70, suggesting that 
the cAMP rise was required for  the constitution of the trimeric complex. 
CHIP mutant (K30A) was used as negative control. 
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Figure 9. HEK293 cells were transfected with V5-HSP70 and Myc-
CHIP (wt or mutant K30A). 24 hours after transfection, cells were 
treated with FSK for 15 minutes and harvested. Lysates were 
immunoprecipited with anti-PKAc antibody and the precipitates were 
immunoblotted with the described antibodies. 
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3.4 CHIP ubiquitinates PKA-C 
The data above indicate that PKA-C, CHIP and HSP70 constitute a 
trimeric complex in cell extracts. Next, I asked if CHIP ubiquitinates 
PKA-C. To this aim, I transfected HEK293 cells with either CHIP (wt or 
mutant K30A) and HA-ubiquitin, and tested the accumulation of 
ubiquitinated PKA-C under growth conditions. The data shown in fig. 10 
indicates that CHIP promoted polyubiquitination of PKA-C. As expected, 
CHIP mutant (K30A) failed to ubiquitinate PKA-C. 
    
 
Fig.10. HEK293 cells were co-transfected with anti HA-ubiquitin and 
CHIP (wt or mutant K30A). 24 hours after transfection, cells were 
harvested. Lysates (1 mg) were immunoprecipited with anti-PKA-C 
antibody and immunoblotted with the indicated antibodies. 
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Since cAMP promotes PKA-C degradation through the UPS, I asked 
if CHIP ubiquitinates PKA-C following cAMP stimulation. To this aim, I 
performed the ubiquitination assay in cells expressing the CHIP mutant 
(K30A) and treated with the β-agonist Isoproterenol, a potent cAMP 
agonist. As expected, the K30A mutant reversed the isoproterenol-
induced ubiquitination of PKA-C (Fig 11). 
                  
 
Fig 11. HEK293 cells were co-transfected with vectors encoding for HA-
ubiquitin and mutant K30A. 24 hours after transfection, cells were 
treated with Isoproterenol and harvested 60 minutes later. Lysates (1 
mg) were immunoprecipitated with anti-PKA-C antibody and 
immunoblotted with the indicated antibodie 
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3.5 CHIP degrades PKA-C. 
The data described above indicate that CHIP constitutes a complex with 
PKA-C and HSP70, hence causing PKA-C poly-ubiquitination. 
Accordingly, I tested if CHIP was responsible of cAMP-induced 
degradation of PKA-C. To this aim, endogenous CHIP was down-
regulated by RNAi. Cells were transfected were control siRNAs or 
siRNAs targeting endogenous CHIP. Tweenty-four hours from 
transfection, cells were left untreated or stimulated with FSK, to 
stimulate the PKA-C degradation. As shown in Fig.12a and Fig.12b, 
down-regulation of CHIP prevented PKA-C degradation induced by FSK 
treatment. 
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        a) 
                             
       b) 
                   
 
Fig 12. a) HEK293 cells were transfected with control siRNA or with 
siRNAs targeting CHIP. 48 hours after transfection, cells were treated 
with FSK for 6 and 9 hours. Lysates were immunoblotted with the 
indicated antibodies. b) Cumulative data of the experiment shown in a. 
 
 
 
 
 
 
 
3.6 Inhibition of HSP70 inhibited PKA-C degradation by cAMP. 
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Published work from different laboratories demonstrate that CHIP 
requires HSP70 to ubiquitinate a given substrate (Feder- Hofmann, 
1999; Imai, Yashiroda, 2003). Accordingly, I tested if pharmacological 
inhibition of HSP70 activity prevents PKA-C degradation. To this end I 
used an inhibitor (VER155008) that specifically targets HSP70, leaving 
working other HSPs. As shown in fig.13, treatment with VER155008 
prevented the degradation of PKA-C induced by FSK. 
 
                       
 
Fig.13 HEK293 cells were treated with the HSP70 inhibitor 
(VER155008, 40 uM), FSK (40 uM) or with both. Cells were harvested 
at the indicated times and lysates were immunoblotted with anti-PKA-C 
and anti-tubulin antibodies. 
 
 
 
 
 
 
 
3.7 HSP70/CHIP complex regulates cAMP-dependent CREB 
phosphorylation. 
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Once activated, PKA-C translocates to the nucleus and 
phosphorylates the transcription factor CREB at Ser133, promoting 
phospho CREB/coactivator-dependent activation of gene transcription 
(Lonze et al. 2002). Given the role of HSP70/CHIP complex in the 
regulation of PKA-C stability, I asked if CREB phosphorylation at the 
PKA site was regulated by the complex. To this aim, I transfected 
HEK293 cells with the CHIP-K30A mutant and treated the cells with 
FSK for different times. As shown in Fig 14, expression of the K30A 
mutant enhanced CREB phosphorylation at Ser133, suggesting a role 
of CHIP in the regulation of CREB activity. To confirm that enhanced 
CREB phosphorylation in K30A expressing cells was, indeed, 
dependent on PKA, I treated the transfected cells with H89, a specific 
inhibitor of PKA.  As predicted, the treatment with H89 reversed the 
effect elicited by K30A overexpression, causing a severe reduction of 
CREB phosphorylation in FSK-treated cells. 
                                                                                  
 
Fig 14. HEK293 cells were transfected with CHIP-K30A and treated 
FSK (40uM) for 30’, 60’ and 90’. Where indicated the cells were 
pretreated with with H89 (10uM). Lysates were immunoblotted with the 
indicated antibodies. 
 
As shown in Fig. 15a and Fig. 15b, genetic silencing of endogenous 
CHIP confirmed the role of the ligase in the regulation of PKA-
dependent phosphorylation of CREB. 
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             a) 
                             
             b) 
                      
Fig. 15. a) HEK293 cells were transfected with control siRNA or with 
siRNA targeting endogenous CHIP. 48 hours after transfection, cells 
were left untreated or stimulated with FSK and harvested at the 
indicated times. Lysates were immunoblotted with the indicated anti-
phospho CREB and anti-Tubulin antibodies. b) Quantitative analysis of 
experiment shown in a). 
 
 
 
 
Next, I tested if HSP70 inhibition enhances CREB phosphorylation. 
To this aim, I treated the cells with HSP70 inhibitor and FSK, and 
evaluated CREB phosphorylation under basal and FSK stimulation. Fig. 
16 shows that HSP70 inhibition enhanced CREB phosphorylation, even 
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in the absence of FSK, and the levels of pohsphoCREB were 
insensitive to FSK treatment.   
                                                                 
    
Figure 16. HEK293 cells were treated with FSK (40 uM). Where 
indicated, cells were pretreated with the HSP70 inhibitor (VER155008, 
40 uM). Cells were harvested at the indicated times and lysates were 
immunoblotted with anti-phosphoCREB and anti-CREB antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
3.8 HSP70/CHIP complex regulates c-fos transcription. 
The binding of phosphoCREB to a cAMP responsive element (CRE) 
located within the c-fos gene promoter drives the transcription of the 
HSP70 I 
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downstream gene (56). Considering the role of HSP70/CHIP complex in 
the regulation of CREB phosphorylation, I tested if PKA-dependent c-
fos transcription was regulated by CHIP. To this aim, I transfected 
HEK293 cells with control siRNA or with siRNA targeting CHIP. Cells 
where, then, treated with FSK and harvested at different time points 
from stimulation. By Real Time-PCR, I monitored the accumulation of c-
fos mRNA under basal condition or following FSK stimulation, both in 
control and in CHIP-silenced cells. As shown in fig.17, activation of 
adenylate cyclase in control cells induced a robust increase of c-fos 
mRNA, at 30 and 60 minutes from treatment. In contrast, 
downregulation of CHIP enhanced basal transcription of c-fos by 
several folds over control values, without further increase of c-fos 
mRNA levels following FSK treatment.  
 
 
 
                 
Figure 17 HEK293 cells were transiently transfected with control siRNA 
or with siRNA targeting endogenous CHIP. 48 hours after transfection, 
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cells were deprived of serum for 18 h and then treated with FSK for 30 
and 60 minutes. Total RNA was extracted and subjected to RT-qPCR 
analysis for c-fos mRNA. 
 
 
 
 
 
 
 
 
 
 
3.9 HSP70 specific inhibitor prevent PKA-C degradation and 
promotes CREB phosphorylation in mouse brain. 
Given the role of PKA in enhancing the neurotransmitter release at 
the synaptic connections (57), I tested if the regulatory mechanism of 
PKA action by CHIP was also operating in the mouse brain. To this aim, 
I performed an intracerebroventricular  (icv) injection of the HSP70 
specific inhibitor in C57B6 mice. 30 minutes later, the same brain area 
was perfused with isoproterenol. The mice were sacrified at different 
time points from stimulation and the hyppocampal tissues explanted. 
Tissue were homogenized and total lysates were immunoblotted for 
PKA-C and phosphoCREB. Fig. 18 shows isoproterenol treatment 
reduced the levels of PKA-C in the hippocampal sections, compared to 
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basal values. As expected, pre-treatment with the HSP70 inhibitor 
increased the levels of PKA-C subunit in the hippocampal lysates, both 
in basal conditions as well as under isoproterenol treatment, by several 
folds over control values.  
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Figure 18. a) Hippocampal slices from mice treated with isoproterenol 
for 30 and 60 minutes or from mice pretreated with HSP70 inhibitor 
before the Isoproterenol treatment were homogenized and lysed. The 
lysates were immunoblotted with the indicated antibodies. b) 
Quantitative analysis of experiment shown in a). 
 
 
 
 
 
 
The same experiment was performed to analyze the levels of 
phosphoCREB. As shown in Fig. 19a and Fig. 19a, icv injection of 
VER155008 increased the basal levels of phosphorylated CREB, 
compared to the controls, and no further induction could be seen after 
isoproterenol treatment.  
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                   b) 
                       
Figura 19. a) Hippocampal tissue explanted from control mice, treated with 
isoproterenol for 30 minutes, and from mice injected with HSP70 inhibitor 
before the isoproterenol treatment. The tissues were homogenized and the 
lysates were immunoblotted with the described antibodies. b) Quantitative 
analysis of experiment shown in a). 
 
3.10 HSP70 inhibitor enhances L-LTP in mouse brain 
Finally, I investigated the electrophysiological consequences of HSP70 
inhibition on Long-Term Potentiation (LTP) at perforant pathway to 
granule cell synapses (PP-DG). We monitored the late phase of LTP (L-
LTP) that is a typical a PKA-dependent form of memory (Malleret et al, 
2010).  Isolated brain slices were treated with FSK and Rolipram, an 
inhibitor of cAMP phosphodiesterases. We monitored the excitatory 
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post-synaptic potentials over a time period from stimulation. This 
protocol induced a potent L-LTP in control slices. As expected, 
inhibition of HSP70 prolonged the L-LTP compared to control slices, 
suggesting a role of HSP70/CHIP/PKA-C complex in cAMP-dependent 
events underlying to long-term memory in the brain (fig 20).   
                     
Figure 20. Time plot of field excitatory post-synaptic potential responses for 
group data, showing that the stimulation with FSK and Rolipram elicits normal 
LTP in controls, and prolonged LTP in VER155008-treated brain slices. 
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4. CONCLUSIONS AND  
DISCUSSION 
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4.1 Discussion 
Activation of PKA is followed by a refractory phase in which the cell 
does not respond to a subsequent stimulus until it returns to its resting 
state. The attenuation of the cAMP response is controlled at different 
steps: desensitization of the membrane receptors, inhibition of 
adenylate cylase, activation of phosphodiesterases and of Ser/Thr 
phosphatases (Canettieri et al., 2003; Lamas and Sassone-Corsi, 
1997)(31, 58).  Work by Armstrong and colleagues showed that, in 
course of hormone stimulation, inhibition of PKA-C translation caused a 
reduction of PKA-C levels and hence attenuation of PKA pathway. This 
was considered as the main mechanism responsible of the refractory 
phase in hormone-responsive cells (Armstrong R et al., 1995) (30). 
Accordingly, PKA activity can be down regulated by decreasing the 
amount of free catalitic subunit or increasing the levels of the inhibitory 
regulatory subunits.  
The UPS could contribute to the attenuation of the cAMP signaling at 
different steps. At cell membrane, ubiquitination and consequent 
proteolysis of receptors determines post-stimulus receptor 
desensitization (Bonifacino and Weissman, 1998) (41). Stimulatory Gas 
subunit and PDEs undergo to ubiquitination and proteasomal 
degradation, with significant consequences on the activated 
downstream signaling (Jenie et al., 2013; Huo et al., 2012)(59, 60). The 
UPS can also sustain the cAMP cascade. Thus, ubiquitin-directed 
proteolysis of R subunits by the RING ligase praja2 contributes to 
increase free PKA-C levels and to activate the downstream effectors of 
PKA (Lignitto et al., 2011) (55). Despite the wide range of biological 
activities controlled by PKA and the efforts to identify the regulatory 
mechanisms of PKA action, if and how the PKA-C subunit can be 
regulated by the UPS was largely unexplored. 
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Our work contributed to identify a novel mechanism of cAMP 
attenuation mostly mediated by the ubiquitination and proteolysis of 
PKA-C, creating a novel link between cAMP signaling and the UPS. 
The data shown in my thesis demonstrate that, following cAMP burst, 
PKA-C undergoes to proteolitic degradation. Interfering with the 
proteasome activity prevented the decline of PKA-C levels in course of 
GPCR stimulation. I have identified the HSP70/CHIP complex as 
responsible of PKA-C ubiquitination following cAMP stimulation. 
Interfering with the expression or activity of CHIP prevented PKA-C 
ubiquitination and proteolysis induced by cAMP. I found that HSP70 
was in complex with PKA-C, even in the absence of external stimuli. 
Rise of cAMP levels induced recruitment of the E3 ligase CHIP within 
the complex, activating the negative-feedback regulatory loop. The 
molecular events controlled by HSP70/CHIP complex deeply impacted 
on PKA signaling. In particular, I observed that phosphorylation of 
CREB at the PKA site (Ser133) and the transcription of CREB-
responsive genes, as c-fos, were up-regulated when CHIP was 
silenced. 
HSP70 mediates the physical and functional interaction between 
CHIP and PKA-C. Thus, inhibition of HSP70, both in cells and in mouse 
brains, caused accumulation of PKA-C and consequent enhancement 
of CREB phosphorylation. The role of HSP70 in controlling PKA-C 
activity was confirmed by studying the electrophysiological events 
underlying to brain memory. Thus, treatment of hippocampal sections 
with the HSP70 inhibitor enhanced cAMP-induced form of LTP. Studies 
are in course to confirm these data by injecting the HSP70 inhibitor in 
the hippocampus of living mice and evaluating the electrophysiological 
events of such pharmacological treatment on the LTP. Furthermore, 
available CHIP KO mice will be analyzed to better understand  the role 
of this ligase in the induction and maintenance of long term memory.  
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this is the first demonstration of attenuation of the cAMP signaling, 
based on the regulation of the stability of activated kinase (Fig. 21). 
 
 
Figure 21. Proposed model. Under resting conditions, the tetrameric 
PKA holoenzyme is inactive.  The binding of a given ligand to its 
cognate GPCR at plasma membrane turns ON the cAMP signaling, 
inducing dissociation of PKA holoenzyme and release of of free active 
PKA-C. Phosphorylation of a wide array of intracellular substrates by 
PKA regulates key biological functions. Following the burst phase, 
ubiquitination and proteolysis of PKA-C by CHIP-triggered UPS 
attenuates the PKA cascade.  
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According to the proposed model, the pathological conditions caused 
by inactivating mutations of CHIP, as it occurs in autosomal recessive 
spinocerebellar ataxia (SCAR16), could be a consequence of impaired 
functioning of the cAMP pathway. Therefore, restoring cAMP cascade 
in SCAR16 disease may have potential therapeutic effect on the 
progression of the disease. The mechanism regulated by CHIP can be 
also relevant in proliferative diseases, for example in those linked to 
tumor progression and metastasis. In this context, a recent work by 
Pattabiraman et al. shows that activation of PKA induces a 
mesenchymal-to-epithelial transition (MET) in metastatic mammary 
epithelial cell, preventing the growth and expansion of the metastatic 
mesenchimal tumor cells.  Activation of PKA induces an epigenetic 
reprogramming of tumor initiating cells (TICs) which promotes their 
differentiation and loss of tumor-initiating properties (Pattabiraman et 
al., 2016)(61). In this context, it would be of interest to test the role of 
CHIP in MET of mesenchimal cancer cells and evaluate the 
consequence of CHIP inactivation or pharmacological inhibition of 
HSP70 in the growth and progression of metastatic epithelial lesions.  
In conclusions, my work contributed to identify a novel mechanism of 
cAMP signal attenuation operating in mammalian cells that is required 
for post-stimulus recovery phase in hormone-stimulated cells. Exploring 
further the mechanism(s) regulating ubiquitination of PKA-C in course of 
hormone stimulation, and identifying other UPS targets in the cAMP 
cascade will provide important tools to dissect and manipulate this 
signaling network in human disorders. 
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5.METHODS 
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5.1 Cell lines.  
Human embryonic kidney cell line (HEK293) were cultured in Dulbecco 
modified Eagle’s medium, containing 10% fetal bovin serum in an 
atmosphere of 5% CO2. 
5.2 Plasmids and transfection.  
Vectors encoding the Myc-tagged CHIP and the Myc-tagged Chip K30A 
were provided by Dr. Francesca Carlomagno (University of Naples, 
Italy). V5-HSP70 was purchased from Addgene, HA-tagged ubiquitin 
was provided by Dr. Antonio Leonardi (University of Naples, Italy), HA-
tagged PKA catalytic subunit type alpha was provided by Dr. Eduard 
Stefan ( University of Innsbruck, Austria).PKA K310A and PKA K286A 
were generated by  site-directed mutagenesis. siRNA targeting coding 
regions of CHIP were purchased from Life Technologies. The following 
is the siRNA sequence, targeting CHIP: 
Sense sequence : UUACACCAACCGGGCCUUtt 
Antisense sequence : CAAGGCCCGGUUGGUGUAAta 
siRNA were transiently transfected using Lipofectamine 2000 
(Invitrogen) at a final concentration of 100 pmol/ml of culture medium. 
 
5.3 Antibodies and chemicals.  
Rabbit polyclonal antibodies directed against PKA alpha catalytic 
subunit (immunoblot 1:4000), α-actin (immunoblot 1:2000) and CHIP 
(immunoblot 1:500) were bought from Santa Cruz; Myc epitope 
(immunoblot 1:2000), V5 epitope (immunoblot 1:2000) and α-tubulin 
(immunoblot 1:8000) from Sigma; CREB (immunoblot 1:1000) and 
pCREB (immunoblot 1:1000) from Millipore; hemaglutinin epitope 
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(immunoblot dilution 1:1000) (HA.11) from Covance. Forskolin was 
purchased from SIGMA and VER 155008 from Tocris Bioscience. 
5.4 Western Blot Analysis. 
Cells were washed twice with phosphate-buffered saline and lysed in 
saline buffer-1% Triton-X 100 (NaCl, 150 mM; Tris-HCl, 50 mM, pH8; 
EDTA, 5 mM) or, for immunoprecipitation assay, in saline buffer 0.5% 
NP40 (50mMTris-HCl, pH 7.4, 0.15MNaCl, 100 mM EDTA,0.5% NP40) 
containing aprotinin (5 μg/ml), leupeptin (10 μg/ml), pepstatin (2 μg/ml), 
0.5 mm PMSF, 2 mmorthovanadate, and 10 mmNaF. 
The lysates were cleared by centrifugation at 15,000 g for 10 min. An 
aliquote of whole cell lysate (WHL) (100 μg) were resolved on sodium 
dodecyl sulfate polyacrylamide gel (SDS-PAGE) and transferred on 
nitrocellulose membrane (Biorad, Milan, Italy) for 3 h. Filters were 
blocked for 1 h at room temperature in Tween-20 Phosphate buffer 
saline (TPBS) (PBS- Sigma, 0,1% Tween 20, pH 7.4) containing 5% 
non-fat dry milk. Blots were then incubated O/N with primary antibody. 
Blots were washed three times with TPBS buffer and then incubated for 
1 h with secondary antibody (peroxidase-coupled antirabbit (GE-
Healthcare) in TPBS. Reactive signals were revealed by enhanced ECL 
Western Blotting analysis system (Roche). 
5.5 Immunoprecipitation and pull down assay. 
 Cells were homogenized in lysis buffer described above. Cell lysates 
(1.5 mg) were immunoprecipitated with the indicated antibodies. An 
aliquot of cell lysate (50 g) or immunoprecipitates were resolved by 
SDS-PAGE gel and transferred to Protran membrane. The immunoblot 
analysis was performed as previously described. Pellets were washed 
four times in lysis buffer supplemented with NaCl (0.4 M final 
concentration) and eluted in Laemmli buffer. Eluted samples were 
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resolved on8%-SDS PAGE gel, transferred to nitrocellulose membranes 
and immunoblotted with the indicated antibody.  
5.6 Protein extraction from murine brain tissue.  
The tissue removed from the animal, was immediately placed in 5 
volumes of Lysis buffer 1% Triton with DOC 0,5 %. The tissue was then 
homogenized on ice using an homogenizer. The sample was cleared by 
centrifugation for 10 minutes at 13000 RPM (4°C) and the supernatant 
was collected in 1,5 ml tube. 
5.7 Electrophisiology.  
All animal procedures were in compliance with the European Council 
Directive (86/609/EEC). Parasagittal hippocampal slices (400  μm) from 
mice were kept submerged at 30  °C and superfused (2–3  ml  min−1) 
with oxygenated (95% O2, 5% CO2) artificial cerebrospinal fluid (ACSF) 
containing (mM): 124  NaCl, 2.5  KCl, 1.25   NaH2PO4, 1.3   MgSO4, 
2.4   CaCl2, 26   NaHCO3 and 10 glucose. Slices were treated with 
VER 155008(40 uM)for 30 minutes before stimulation. Presynaptic 
stimulation was applied to the medial perforant pathway of the dentate 
gyrus using a bipolar insulated tungsten wire electrode, and field 
excitatory postsynaptic potentials were recorded at a control test 
frequency of 0.033  Hz from the middle one-third of the molecular layer 
of the dentate gyrus with a glass microelectrode. The transient E-LTP 
was induced by treatment with Forskolin (50 uM), whereas long-lasting 
L-LTP was induced with TBS consisting of nine bursts of four pulses at 
100  Hz, 200  ms interburst interval, 5  min intertrain interval. All 
solutions contained 100  μM picrotoxin (Sigma) to block GABAA (γ-
aminobutyric acid A)-mediated activity. 
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5.8 Animals.  
C57 black mice (Charles River) were housed in diurnal lighting 
conditions (12  h darkness and 12  h light) and fasted overnight but 
allowed free access to water before the experiment. Experiments were 
carried out according to international guidelines for animal research and 
the experimental protocol was approved by the Animal Care Committee 
of the University of Naples. 
5.9 Chemicals administration into the rat brain. 
 All mice, anaesthetized with chloral hydrate (400  mg  kg−1, 
intraperitoneally), were put on a stereotaxic frame. A 23  g stainless-
steel guide cannula (Small Parts) was implanted into the right lateral 
ventricle, the third ventricle, using the stereotaxic coordinates of 
0.5  mm caudal to bregma, 2  mm lateral and 2.5  mm below the dura. 
The cannula was fixed to the cranium using dental acrylic and small 
screws. VER 155008 (40uM) was administered 1  hour before 
isoproterenol stimulation. Rats were killed 30  min or 60  min later. 
Distinct brain regions (cortex, hippocampus and striatum) from the left 
and right hemispheres were isolated. Brain tissues were used for 
immunoblot analysis and RNA extraction. 
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